Investor Relations Center
Company profile
Medinice S.A. conducts research and development of innovative medical devices in cardiology. Its main projects include PacePress (a compression band used after implantation of cardiac devices), AtriClamp (a clamp for left atrial appendage closure), and CoolCryo (a cryoapplicator for cardiac surgical ablation). The Company focuses on prototype development, preclinical and clinical testing, and obtaining patents.
Stock price
Medinice S.A. shares have been listed on the Main Market of the Warsaw Stock Exchange since December 30, 2020. Previously, on September 25, 2018, the Company debuted on the NewConnect market.
Sector: medical equipment and supplies
ISIN: PLMDNCE00016
Ticker: ICE.WA
Latest news
- 2026-04-29
Medinice Completes CoolCryo Clinical Investigation and 6-Month Patient Follow-Up
Medinice completed the CoolCryo clinical investigation and 6-month patient follow-up, with all participants in good health. Results confirmed the device’s safety and support further MDR regulatory work, CE marking and commercialization in Europe.
- 2026-04-21
Medinice Commences Due Diligence Process for CoolCryo
Medinice has launched a second due diligence process for CoolCryo with a major international industry player, potentially leading to its acquisition. CoolCryo received FDA 510(k) clearance in February 2026.
Events and presentations
- March 12, 2026
Medinice CEO in BIZNES24’s 'Company Under the Spotlight' Interview [PL]
- May 30, 2025
CoolCryo video for the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2025 conference
Previous events
Latest company reports
- The latest periodic report2026-08-28 17:06
Consolidated semi-annual report for H1-2026
- The latest current report2026-08-31 08:36 | ESPI 40/2026
Positive results of the clinical study of the CoolCryo cryoablation system
- 2026-08-21 16:04ESPI | 39/2026Change of the publication date of the consolidated report for H1-2026See more reports2026-08-13 20:46ESPI | 38/2026Conditional registration of Series O shares in the National Depository for Securities and admission and introduction of Series O shares to trading
Additional information
General MeetingsLearn more
Corporate documentsLearn more- Investor's calendarTimetable for the Release of Periodic Reports in 2026
- Annual report for 2025: Mar 18, 2026
- Report for Q1-2026: May 29, 2026
- Report for H1-2026: Sept 11, 2026
- Report for Q3-2026: Nov 6, 2026
Leadership TeamLearn more- Dividend policyOn July 1, 2019, the Management Board of Medinice S.A. adopted a resolution regarding the Company’s dividend policy. In the event that the Company generates a profit eligible for distribution, the Management Board intends to annually submit a proposal to the Ordinary General Meeting for the payment of a dividend, based on the following parameters:
- Profit for distribution and total dividend payout
- 15 - 50 million PLN: at least 50% of profit to be distributed
- 50 - 100 million PLN: at least 60% of profit to be distributed
- Above 100 million PLN: at least 75% of profit to be distributed
Capital Group Structure
Investor contact
Investor Relations
We Care About Your Privacy
Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience.
Privacy Policy